Stock Mumak

Stock Profile

Apple

Apple delivers a record quarter with strong iPhone growth, billion-dollar profits, and new AI innovations. Here's what's behind the latest developments.

Stock Snapshot

Apple Logo
Table HeaderTable Header
CompanyApple Inc.
SectorTechnology
ThemeConsumer electronics, digital services, artificial intelligence
Business ModelGlobal technology corporation that combines premium hardware, proprietary software, and recurring digital services within an integrated ecosystem
ISINUS0378331005
Market Capitalizationapprox. 4.6 trillion US dollars
UMBRELLA StatusActive

Price Performance (12 Months)

Mumak Score Card

Geopolitics

Industry

Fundamentals

Sentiment

Technical Analysis

Aktuelle Unternehmensmeldungen

Apple Inc.
Technology

Valuation Analysis: Apple

ISIN: US0378331005

Apple exceeded expectations with its latest quarterly figures, achieving the strongest June quarter in its history. While iPhone and Mac sales increased significantly, investors’ attention is increasingly turning to Apple Intelligence, the next generation of Siri, and the long-term growth opportunities of the services business. At the same time, issues such as AI competition, supply chains, and margin development remain crucial for the further development of Apple stock.
Compass 4 out of 5
Active icon
More research

Latest Portfolio Updates

TKMS
Company Update

TKMS – Q3 2026 Earnings Update

TKMS increases revenue by 19% and raises guidance. The high order backlog supports long-term growth prospects.
Next Update
Company Update

RED HOT CHILI mumak of the Week: SpaceX – Technical Chart Picture Brightens Significantly

Following the significant recovery from the August low and a noticeable improvement in the short-term chart setup, SpaceX receives the
Next Update
Weekly Update

Weekly Market Overview – August 3-August 9, 2026

Palantir impresses with strong growth. The UMBRELLA strategy also focuses on healthcare, European defense, and structural trends.
Next Update
Company Update

MUMAK SpotLight of the week: Five stocks in focus

Eli Lilly, Rheinmetall, Bayer, Palantir, and Revolution Medicines impress with strong developments—but valuation, risks, and chart technicals remain decisive.
Next Update